// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:
C
Clinical-grade nanopore sequencing is ready for primary diagnostic use today
Increasingly true for SVs and methylation; SNV calling is competitive but not yet a default reimbursable replacement.
Module 02 · Reading the Genome: Platforms & Modalities →C
AlphaMissense should be used as primary clinical evidence today
Strong benchmark performance, but ClinGen has not yet defined formal evidence-strength tiers; treat as supporting.
Module 03 · Variant Interpretation: ACMG, VUS, and Penetrance →C
Adjuvant chemotherapy intensification based on ctDNA MRD improves overall survival
DFS signal in DYNAMIC; OS benefit not yet established. Active phase III work.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →C
Multi-cancer early detection (MCED) tests like Galleri reduce cancer mortality in average-risk adults
Sensitivity for stage I disease modest (~17%); SYMPLIFY shows utility for symptomatic triage; mortality endpoint requires NHS-Galleri readout.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →C
Lowering your methylation-age via diet and exercise reduces personal mortality risk
Plausible from epidemiology; no RCT with a hard endpoint has demonstrated it.
Module 07 · The Epigenome and Methylation Clocks →C
Mediterranean diet produces durable methylation-age reductions
Suggestive evidence (NU-AGE, PREDIMED subanalyses); effect sizes small, replication mixed.
Module 08 · Lifestyle Inputs to the Epigenome →C
CD19 CAR-T induces durable remissions in refractory autoimmune disease (SLE, myositis, systemic sclerosis)
Schett group case series and small trials are striking; no controlled phase 3 yet.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →C
Routine CHIP screening of asymptomatic adults improves outcomes
No RCT evidence; CHRS gives risk stratification but no validated intervention.
Module 11 · Clonal Hematopoiesis & Aging Genomes →